Parkinson’s UK invests £2.1 million in Neumora Therapeutics for preclinical testing of new Parkinson’s drug

Parkinson’s UK is investing £2.1million to support Neumora Therapeutics to carry out preclinical testing of NMRA-NLRP3, a NLRP3 inhibitor with the potential to reduce inflammation and protect brain cells in Parkinson’s. NLRP3 is a protein that plays a role in regulating a number of inflammatory processes that are believed to contribute to the damage to brain cells that underlies Parkinson’s.

How is academic achievement linked to wellbeing?

This comprehensive study explores the connection between anxiety, cognitive function, and academic success, advocating for holistic educational strategies.

March 13, 2025

Loma Linda Residents Vote to Unionize, but Still Face Pushback

Residents and fellows at Loma Linda University Health in California succeeded in their National Labor Relations Board (NLRB) vote, the latest in a flood of

July 22, 2023

Opinion | Diversity Action Plans for Clinical Trials: Evaluating FDA’s Draft Guidance

Lazarus is an adjunct professor of psychiatry. Jernigan is chief operating officer of a service provider for participants in clinical trials. The FDA is intent

September 7, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.